Ability Pharmaceuticals has a research collaboration with Dr. José Miguel Lizcano's laboratory at the Department of Biochemisty, Faculty of Medicine of the Autonomous University of Barcelona, in Bellaterra.

Ability Pharmaceuticals Phase II clinical studies performed at the Department of Oncology at the Vall d'Hebron University Hospital. Dr. Ana Oaknin is the Principal Investigator.

Ability Pharmaceuticals has research collaborations with the Area of Molecular and Translational Oncology of the IDIBAPS (Institut d'Investigacions Biomèdiques August Pi i Sunyer), associated with the Hospital Clinic de Barcelona and the University of Barcelona. The Area is led by Dr. Pere Gascon.

Ability Pharmaceuticals conducted the Phase I/Ib clinical trials at the Medical Oncology Service and at the Clinical Institute of Hemato-Oncological Diseases y (ICMHO) of the Hospital Clinic de Barcelona. Dr. Laura Vidal was the Principal Investigator.

Ability Pharmaceuticals perform the phase II clinical studies in the Catalan Institute of Oncology (ICO) in the centers of L'Hospitalet, Girona and Badalona. Dr. Ernest Nadal, Dr. Joaquim Bosch and Dr. Teresa Moran are the principal investigators, respectively.

​
Ability Pharmaceuticals has a research collaboration with Dr. Teresa Puig's laboratory at the Department of Molecular Oncology, Faculty of Medicine of the University of Girona (Catalonia).

Ability Pharmaceuticals has a research collaboration with Dr. Xavier Matias-Guiu, head of pathological anatomy at Bellivtge Hosptial and Arnau de Vilanova Hospital and director of Biomedical Research Institute of Lleida (IRB). The collaboration also includes Dra. Nuria Eritja, head of the pathological laboratory and oncology group at IRB, and Dra. Eva Colàs, principal investigator currently in Vall d’Hebron Institut de Recerca (VHIR), Barcelona.

Ability Pharmaceuticals has a research collaboration with Dr. Miguel Segura's laboratory of the Tranlational Research in Pediatric Carcer Group of the Vall d’Hebron Institut de Recerca (VHIR), Barcelona.

Medalchemy has developed the synthetic routes of the drug candidates being developed by Ability Pharmaceuticals and is proceeding to the escalation of their production.
 
Medalchemy is base at the Science Park of the University of Alicante/Alacant.
 

We belong to the ENS-CCA, a group of active researchers with a broad interest in cholangiocarcinoma clinical area, which has significantly contributed to the study into the pathophysiology of the biliary tree and development/onset of cholangiocarcinoma, and pursuing basic, translational and clinical research in an effort to identify treatment options with successful outcome for this type of cancer.